prikaz prve stranice dokumenta Kardiovaskularna sigurnost oralnih antidijabetika.
  Download
PDF 396.43 KB
Scientific paper - review paper
Kardiovaskularna sigurnost oralnih antidijabetika.
Cardiologia Croatica, 11 (2016), 7; 285-294. https://doi.org/10.15836/ccar2016.285
Zaputović, Luka; Rubeša Miculinić, Željka; Matijević Rončević, Sanja; Gobić, David; Zaninović Jurjević, Teodora

Related files
zaputovic-2016-kardiovaskularna_sigurnost_oralnih_antidijabetika-medri_1768-publishedversion-cardiologia_croatica_2016_11_7_285_294-3mkeit-s.pdf
PDF 396.43 KB
Cite this document

Zaputović, L., Rubeša Miculinić, Ž., Matijević Rončević, S., Gobić, D. & Zaninović Jurjević, T. (2016). Kardiovaskularna sigurnost oralnih antidijabetika.. Cardiologia Croatica, 11. (7), 285-294. doi: 10.15836/ccar2016.285

Zaputović, Luka, et al. "Kardiovaskularna sigurnost oralnih antidijabetika.." Cardiologia Croatica, vol. 11, no. 7, 2016, pp. 285-294. https://doi.org/10.15836/ccar2016.285

Zaputović, Luka, Željka Rubeša Miculinić, Sanja Matijević Rončević, David Gobić and Teodora Zaninović Jurjević. "Kardiovaskularna sigurnost oralnih antidijabetika.." Cardiologia Croatica 11, no. 7 (2016): 285-294. https://doi.org/10.15836/ccar2016.285

Zaputović, L., et al. (2016) 'Kardiovaskularna sigurnost oralnih antidijabetika.', Cardiologia Croatica, 11(7), pp. 285-294. doi: 10.15836/ccar2016.285

Zaputović L, Rubeša Miculinić Ž, Matijević Rončević S, Gobić D, Zaninović Jurjević T. Kardiovaskularna sigurnost oralnih antidijabetika.. Cardiologia Croatica [Internet]. 2016 June 30 [cited 2024 November 12];11(7):285-294. doi: 10.15836/ccar2016.285

L. Zaputović, Ž. Rubeša Miculinić, S. Matijević Rončević, D. Gobić and T. Zaninović Jurjević, "Kardiovaskularna sigurnost oralnih antidijabetika.", Cardiologia Croatica, vol. 11, no. 7, pp. 285-294, June 2016. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:267130. [Accessed: 12 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)Kardiovaskularna sigurnost oralnih antidijabetika.
Title (english)Cardiovascular Safety of Oral Antidiabetic Drugs.
AuthorLuka Zaputović
AuthorŽeljka Rubeša Miculinić
AuthorSanja Matijević Rončević
AuthorDavid Gobić
AuthorTeodora Zaninović Jurjević
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (croatian)
Hrvatska pripada skupini europskih zemalja s visokim kardiovaskularnim rizikom i rastućom prevalencijom šećerne bolesti tipa 2 (DMT2). Prema podatcima Nacionalnog registra osoba sa šećernom bolešću (CroDiab registar), u Hrvatskoj je 2014. godine bilo evidentirano ukupno 254 296 osoba oboljelih od dijabetesa starijih od 18 godina (7,9 %). DMT2 je, uz hipertenziju i hiperlipidemiju, jedan od vodećih čimbenika kardiovaskularnog rizika. Glavne regulatorne agencije za lijekove, potaknute štetnim kardiovaskularnim učincima rosiglitazona u RECORD studiji i kasnijim metaanalizama, zahtijevaju za sve antidijabetike kliničke pokuse o utjecaju na kardiovaskularne ishode i dokaze o sigurnosti. U procjeni učinka antidijabetika na kardiovaskularni rizik važna je gornja granična vrijednost dvostranog intervala pouzdanosti od 95 % (95 % CI) za procijenjeni omjer rizika. Svi antidijabetici s gornjom granicom omjera rizika 1,3 zahtijevaju dodatne sigurnosne provjere. Kardiovaskularna sigurnost oralnih antidijabetika posebno je važna u bolesnika sa zatajivanjem srca. S obzirom na veliki broj antidijabetika na tržištu, odluka o optimalnom liječenju DMT2 treba ovisiti o svim individualnim karakteristikama bolesnika i procijenjenom kardiovaskularnom riziku.
Abstract (english)
Croatia belongs to a group of European countries with a high cardiovascular risk and growing prevalence of diabetes mellitus type 2 (DMT2). According to data of the National Diabetes Registry (CroDiab registry), a total of 254,296 individuals aged >18 suffering from diabetes were registered in 2014 (7.9%). Along with hypertension and hyperlipidemia, DMT2 is one of the leading cardiovascular risk factors. Prompted by adverse cardiovascular effects of rosiglitazone, demonstrated in the RECORD study and subsequent meta-analyses, the main drug regulatory agencies require clinical trials of the effect on cardiovascular outcomes and safety evidence for all antidiabetic drugs. On assessing the effects of antidiabetic drugs on cardiovascular risk, the two-sided confidence interval upper borderline value of 95% (95% CI) is highly relevant for the estimated risk ratio. Additional safety testing is required for all antidiabetic drugs with the risk ratio upper limit ≥1.3. Cardiovascular safety of oral antidiabetic drugs is of special importance in patients with heart failure. Considering the great number of antidiabetic drugs on the market, decision on optimal DMT2 therapy should be made in dependence of specific characteristics of each individual patient and cardiovascular risk assessment.
Keywords (croatian)
Keywords (english)
Languagecroatian
Languageenglish
Publication typeScientific paper - review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCardiologia Croatica
Numberingvol. 11, no. 7, pp. 285-294
p-ISSN1848-543X
e-ISSN1848-5448
DOIhttps://doi.org/10.15836/ccar2016.285
URN:NBNurn:nbn:hr:184:267130
Publication2016-06-30
Document URLhttp://hrcak.srce.hr/161133
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-10-18 19:31:16